Longevity & Mitochondria

Epithalon (Epitalon)

Also known as Epitalon, Epithalone, AEDG peptide, Ala-Glu-Asp-Gly, Alanyl-glutamyl-aspartyl-glycine

A four-amino-acid peptide designed in St Petersburg as a synthetic stand-in for a bovine pineal gland extract, whose telomerase findings come almost entirely from cell culture rather than from people.

How it works

Upregulates Telomerase, the enzyme that protects and lengthens telomeres (DNA caps).

Performance edge

The foundation of longevity research; studied for its ability to slow cellular decay and restore immune function.

Plain-English guide

Epithalon, without the jargon

What it is

Epithalon, also written Epitalon, is a synthetic peptide made of only four amino acids: alanine, glutamic acid, aspartic acid and glycine, which is why it is also called the AEDG peptide. It was created at the St Petersburg Institute of Bioregulation and Gerontology by Vladimir Khavinson and colleagues as a defined chemical stand-in for Epithalamin, a crude extract of the pineal gland (the small gland in the brain that makes melatonin) taken from cattle. Almost everything written about it traces back to that one research network, and the telomerase result it is famous for comes from cells in a dish rather than from people. It has never been approved as a medicine anywhere, and in the United States it exists only as a compounding-pharmacy and research-chemical item.

What people use it for

General anti-ageing and longevity protocols, which is what the marketing is built around
Sleep and circadian rhythm, the indication the US Food and Drug Administration advisory committee actually reviewed it for in July 2026
Attempts to lengthen telomeres, the protective caps on the ends of chromosomes, based on cell-culture work
Immune support, carried over from trials of the bovine pineal extract rather than from trials of this peptide
Eye conditions such as retinitis pigmentosa, based on a 162-patient Russian trial from 2002 that compared the peptide against the conventional treatment of the day

How it works, simply

Think of each chromosome as a shoelace and the telomere as the plastic tip that stops it fraying. Every time a cell divides the tip gets shorter, and when it runs out the cell stops dividing. Telomerase is the small repair crew that rebuilds the tip, and most adult cells have switched that crew off. The claim for Epithalon is that it switches the crew back on; what has actually been shown is that it does so in cultured human cells, and nobody has measured whether that translates into anything you would notice in your own body.

What to expect, and when

Day 1-10The usual protocol is a short daily course, but no published human study of this peptide reports what people feel during it, so any early effect you read about is anecdote.
End of courseCell-culture work measured telomerase activity and telomere length after days of exposure in a dish; there is no equivalent human measurement to point to at this stage.
Month 3-6Protocols usually repeat a course twice a year. That spacing comes from convention and from the extract trials, not from any dosing study of the tetrapeptide.
Year 3-12The mortality and cardiovascular findings people cite were measured over three to twelve years, but those trials gave Epithalamin, the bovine pineal extract, not this peptide.
Beyond 12 yrsNothing has been published beyond a fifteen-year follow-up, and that follow-up is also of the extract rather than of Epithalon.

Side effects and interactions

No adverse events were reported in the studies located, which is not the same as none existing; the 2025 International Journal of Molecular Sciences review states plainly that information on this peptide's safety is missing
The 2002 retinitis pigmentosa trial reported no side effects in treated patients, but it was neither blinded nor placebo-controlled
Injection-site pain, redness and bruising are the ordinary consequences of subcutaneous injection and are not characterised for this peptide, because no controlled injection trial has been published
Sleep and dream changes are widely reported anecdotally and have not been measured in any published trial
No published data exists on genotoxicity, carcinogenic potential, or interactions with food or other drugs, which the 2025 review lists as a specific gap

Who should avoid it

You are pregnant, trying to conceive, or breastfeeding; no human reproductive data exists for this peptide
You have a current or past cancer diagnosis, or an undiagnosed lump. Telomerase reactivation is a feature of most cancers, and although the rodent work points the other way, this has never been tested in a person with cancer
You are on hormone-sensitive treatment or being monitored for a pineal or pituitary condition, given the claimed effects on melatonin and the neuroendocrine axis
You are a competitive athlete under the World Anti-Doping Agency code, where a substance with no regulatory approval anywhere is prohibited at all times under the non-approved substances category
You are under 18, or you are not working with a physician who knows you are taking it

Common mistakes

Treating the telomere result as a human finding. The telomerase and telomere-lengthening data come from cultured human cells in a dish, and no published study has measured telomere length in a person given this peptide.
Confusing Epithalon with Epithalamin. The long-running mortality trials in elderly cardiac patients used Epithalamin, a bovine pineal extract, not the four-amino-acid synthetic peptide; the two are related but they are not the same product.
Reconstituting with tap or spring water, or shaking the vial. Use bacteriostatic water, run it slowly down the glass, and swirl rather than shake so the peptide is not sheared.
Storing it badly. Keep the lyophilised powder cold and dark, refrigerate once reconstituted, and discard on the timeline your pharmacist gives rather than stretching one vial across a year of twice-yearly courses.
Buying from an unregulated vendor. Analytical chemists have had to identify this exact tetrapeptide in unlicensed pharmaceutical preparations, so what is in the vial is an open question unless it came from a licensed compounder.

Deep research

What the literature actually shows

Mechanism

Epithalon is the tetrapeptide Ala-Glu-Asp-Gly. It was designed as a defined synthetic analogue of Epithalamin, a peptide extract of bovine pineal gland, on the reasoning that the activity of the extract could be reduced to a short amino acid motif. That lineage matters when reading the literature, because the strongest human data belongs to the extract and the strongest mechanistic data belongs to the peptide, and the two are routinely presented as though they were one body of evidence.

The central mechanistic claim is telomerase induction. In telomerase-negative human fetal fibroblasts, adding Epithalon induced expression of the catalytic subunit of telomerase, produced measurable enzyme activity, and elongated telomeres, which the authors interpreted as reactivation of a normally silenced gene (Bull Exp Biol Med, 2003). That finding was reproduced in 2025 by an independent group, which reported dose-dependent telomere lengthening in normal human cell lines through upregulation of hTERT, the catalytic subunit gene, and lengthening in cancer cell lines through the alternative lengthening of telomeres pathway instead (Biogerontology, 2025). Both results are in cell culture.

How a four-residue peptide could reach a gene promoter at all is the weakest link in the model. The proposal is direct nucleic-acid interaction: that very short peptides cross the plasma and nuclear membranes and bind DNA in a sequence-selective manner, with a particular affinity described for CAG-containing sequences, or else bind histones and alter chromatin accessibility. Molecular modelling supporting histone binding accompanies work showing AEDG raised neurogenic marker expression roughly 1.6 to 1.8-fold in human gingival mesenchymal stem cells (Molecules, 2020). No receptor for the peptide has been identified, and the 2025 review states that the mechanism remains unclear after roughly twenty-five years and that physico-chemical and structural investigation of the peptide is still limited (Int J Mol Sci, 2025).

The melatonin story is less settled than the marketing suggests. The peptide is routinely described as restoring pineal melatonin rhythm, and rhythm effects have been reported in aged monkeys and in the extract trials. But an independent group perifusing pineal glands from young and old rats found that the tetrapeptide, at concentrations from ten to the minus four down to ten to the minus six molar, had no significant effect on melatonin secretion at either age and did not modify the melatonin rise induced by isoproterenol, concluding that the peptide plays no regulatory role in melatonin secretion in that model (J Endocrinol Invest, 2003).

Strength of evidence

Limited human dataThe human evidence is small, indirect and almost entirely from one research network: the randomised multi-year trials that produce the widely quoted mortality figures gave Epithalamin, a bovine pineal extract, not this tetrapeptide, and direct human data on the tetrapeptide itself amounts to an unblinded 162-patient retinitis pigmentosa trial against conventional treatment and a 75-woman placebo-controlled melatonin and clock-gene study, both from the originating institute, while the telomerase and telomere findings remain cell culture, though they now have an independent 2025 replication.

Key studies

Human trial2003Neuro Endocrinology Lettersn = 266
Peptides of pineal gland and thymus prolong human life
Elderly and older subjects were followed for six to eight years after bioregulators were applied during the first two to three years. Mortality fell 1.6 to 1.8-fold with Epithalamin, 2.0 to 2.1-fold with Thymalin, 2.5-fold with the two combined, and 4.1-fold when the combination was repeated annually for six years, with acute respiratory disease incidence 2.0 to 2.4-fold lower. The substances given were Epithalamin, a bovine pineal extract, and Thymalin, not the Epithalon tetrapeptide.
Randomised controlled trial2006Bulletin of Experimental Biology and Medicine
Geroprotective effect of epithalamine (pineal gland peptide preparation) in elderly subjects with accelerated aging
A randomised study in elderly subjects with accelerated cardiovascular ageing reported, after twelve years, overall mortality 28 percent lower than control, cardiovascular mortality about two-fold lower, and two-fold lower incidence of cardiovascular failure and of respiratory disease, alongside improved exercise tolerance and reduced functional age. The agent was epithalamine, the pineal gland peptide preparation, rather than the synthetic tetrapeptide.
Randomised controlled trial2011Bulletin of Experimental Biology and Medicinen = 79
Peptide geroprotector from the pituitary gland inhibits rapid aging of elderly people: results of 15-year follow-up
Thirty-nine coronary patients received six courses of epithalamin over three years in addition to basic therapy while forty received basic therapy alone, with follow-up to fifteen years. The treated group showed decelerated cardiovascular ageing, preserved physical endurance, normalised circadian melatonin rhythm and improved carbohydrate and lipid metabolism, with significantly lower mortality. The trial is unblinded, comes from a single research network, and used the extract rather than Epithalon.
Review2025International Journal of Molecular Sciences
Overview of Epitalon-Highly Bioactive Pineal Tetrapeptide with Promising Properties
A review of roughly twenty-five years of AEDG research describing geroprotective, antioxidant, neuroprotective and antimutagenic effects, effects on melatonin synthesis and on interleukin-2 messenger RNA levels, and a proposed interaction with CAG-containing DNA sequences. It cites a series of 162 retinitis pigmentosa patients aged 18 to 72 given parabulbar injections whose visual acuity rose by 0.15 to 0.20 on average with no side effects reported. The authors state that information on the peptide's safety is missing, that the mechanism remains unclear, and that short- and long-term toxicity studies are essential before it could be approved as an active ingredient.
In vitro2003Bulletin of Experimental Biology and Medicine
Epithalon peptide induces telomerase activity and telomere elongation in human somatic cells
Adding Epithalon to telomerase-negative human fetal fibroblast cultures induced expression of the catalytic subunit of telomerase, produced enzymatic telomerase activity, and elongated telomeres. The authors proposed this reflects reactivation of a silenced telomerase gene in normal cells and could extend the proliferative lifespan of cells in culture. This is the origin of essentially every telomere claim made for the peptide.
In vitro2025Biogerontology
Epitalon increases telomere length in human cell lines through telomerase upregulation or ALT activity
An independent group reported dose-dependent telomere lengthening in normal human cell lines through upregulation of hTERT and activation of telomerase, while cancer cell lines instead extended telomeres through the alternative lengthening of telomeres pathway. This is the clearest replication of the 2003 culture result by authors outside the originating network, and it remains cell-culture work.
Human trial2002Neuro Endocrinology Lettersn = 162
Pineal-regulating tetrapeptide epitalon improves eye retina condition in retinitis pigmentosa
The one separately indexed human study of the tetrapeptide itself, indexed in MEDLINE as a controlled clinical trial. Epitalon therapy in patients with degenerative retinal lesions produced a positive clinical effect in 90 percent of cases; the 2025 International Journal of Molecular Sciences review describes the series as 162 patients with retinitis pigmentosa aged 18 to 72 given 5.0 micrograms per eye parabulbarly for 10 consecutive days, with visual acuity rising 0.15 to 0.20 on average and no side effects reported. The trial was unblinded and compared against conventional treatment of the day rather than placebo, and it comes from the St Petersburg institute that originated the peptide. The same abstract also reports retinal work in Campbell rats, so the patient count is taken from the review rather than from the abstract.
Animal study2002International Journal of Cancer
Inhibitory effect of the peptide epitalon on the development of spontaneous mammary tumors in HER-2/neu transgenic mice
Female FVB/N HER-2/neu transgenic mice given 1 microgram of epitalon per mouse for five consecutive days each month showed a reduced cumulative number of mammary tumours and a reduced maximum tumour size relative to control, with HER-2/neu messenger RNA expression 3.7-fold lower in treated animals. The comparison peptide Vilon increased tumour incidence in the same experiment.

Safety data

There is no published safety dataset for this peptide. The 2025 International Journal of Molecular Sciences review, the most recent synthesis available, states that information regarding critical issues about this peptide's safety is missing and that studies of short- and long-term toxicity are essential before it could be approved as an active pharmaceutical ingredient. It specifically names genotoxic activity, carcinogenic potential and food-drug and drug-drug interactions as unstudied. The 2002 retinitis pigmentosa trial reported no side effects in treated patients, but that trial was unblinded and compared against conventional treatment rather than placebo, and absence of reported events in an unblinded trial is weak evidence.

The theoretical concern that matters most is the mechanism itself. Reactivating telomerase is one of the changes that lets a cancer cell divide without limit, so a compound marketed for telomerase induction raises an obvious question. The rodent literature points the other way rather than confirming the fear: in HER-2/neu transgenic mice epitalon reduced mammary tumour number and size and cut HER-2/neu messenger RNA 3.7-fold (Int J Cancer, 2002), and in female C3H/He mice given 0.1 micrograms five times weekly for 6.5 months it reduced malignant tumours and prevented metastases with no toxic effect reported (In Vivo, 2006). But the 2025 cell-culture work also found that cancer cell lines lengthened their telomeres in response, through the alternative lengthening of telomeres pathway, and no study has given this peptide to a person with a cancer history. The question is open, not settled in either direction.

Product quality is a separate risk from the molecule. Analytical chemists publishing in Drug Testing and Analysis in 2015 reported having to identify this tetrapeptide in unlicensed pharmaceutical preparations, a reminder that material bought outside a regulated supply chain may not be what the label says. It is also worth stating plainly that nearly the entire positive literature, including the multi-year mortality trials, originates from a single research network in St Petersburg and has not been independently replicated outside it, the exceptions being the 2025 telomere work and a 2003 melatonin study that returned a negative result.

Regulatory status

FDA: As of 2026-09-19, Epitalon is not approved by the US Food and Drug Administration for any indication; the agency's Pharmacy Compounding Advisory Committee reviewed Epitalon free base and Epitalon acetate for insomnia on 24 July 2026 as candidates for the 503A bulk drug substances list, and any addition would still require notice-and-comment rulemaking before it had legal effect.
WADA: As of 2026-09-19, Epitalon is not named individually on the World Anti-Doping Agency Prohibited List, but because it has no approval from any governmental regulatory health authority for human therapeutic use it falls under section S0, non-approved substances, and is prohibited at all times both in and out of competition.
Source: https://www.fda.gov/advisory-committees/advisory-committee-calendar/july-23-24-2026-meeting-pharmacy-compounding-advisory-committee-07232026

Open questions

Does Epithalon change telomere length in a living human being? Every telomere measurement in the literature is from cultured cells, and no human telomere study of this peptide has been published.
How does a four-amino-acid peptide survive administration, enter a cell, cross the nuclear membrane and reach a gene promoter? No receptor has been identified and the DNA- and histone-binding model rests largely on molecular modelling.
Do the mortality and cardiovascular results from the Epithalamin extract trials transfer to the synthetic tetrapeptide at all, given that the two have never been compared head to head in people?
Is telomerase induction net protective or net risky over decades? The rodent tumour data and the alternative-lengthening finding in cancer cell lines pull in opposite directions.
Why did an independent perifusion study find no effect on melatonin secretion when melatonin restoration is one of the most repeated claims made for this peptide?